Physicians' use of heparin following thrombolytic therapy: An international perspective

Journal of Thrombosis and Thrombolysis

Volumn 4, Issue 3-4, 1997, Pages 415-423

  Berdan, Lisa G ^a   Kleiman, Neal S ^b   Woodlief, Lynn H ^a   Harrington, Robert A ^a   Granger, Christopher B ^a   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Heparin; Myocardial infarction; Thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ARTICLE; DRUG EFFICACY; DRUG USE; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SUBCUTANEOUS DRUG ADMINISTRATION; UNITED STATES;

EID: 0030793732     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008805601821     Document Type: Article

References (32)

1. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987;317:1613-1618.
2. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850-855.
3. O'Rourke M, Baron D, Keogh A, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988;77:1311-1315.
4. National Heart Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1988;1:203-208.
5. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 1:349-360.
7. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525-530.
8. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trail. Lancet 1988;1:842-847.
9. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987;10:527-529.
10. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72:616-620.
11. Rapold HJ, de Bono D, Arnold AE, et al. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia: The European Cooperative Study Group. Circulation 1992;85: 928-934.
12. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992;20:513-519.
13. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66: 1412-1417.
14. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction (HART). N Engl J Med 1990;323:1433-1437.
15. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.
16. Melandri G, Branzi A, Semprini F, Cervi V, Galie N, Magnani B. Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J 1990;64:118-120.
17. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction: ISIS-3. Lancet 1992; 339:753-770.
18. Topol EJ, Armstrong P, Van de Werf F, et al. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol 1992;19:1123-1128.
19. Hlatky MA, Cotugno HE, Mark DB, O'Connor CM, Califf RM, Pryor DB. Adoption of thrombolytic therapy in the management of acute myocardial infarction. Am J Cardiol 1988;61:510-514.
20. Hlatky MA, Cotugno HE, Mark DB, O'Connor CM, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. Am J Cardiol 1988;61:515-518.
21. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
22. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
23. Gunnar RM, Bourdillon PDV, Dixon DW, et al. Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). J Am Coll Cardiol 1990;16:249-292.
24. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
25. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142-154.
26. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989;73:185-190.
27. Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991;83:1534-1542.
28. Granger CB, Califf RM, Hirsh J, Woodlief LH, Topol EJ, for the GUSTO Investigators. aPTTs after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age and sex: experience from the GUSTO Trial. Circulation 1992;86(Suppl I):I-258.
29. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320:352-357.
30. Kaplan K, Davison R, Parker M, Mayberry B, Feiereisel P, Salinger M. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1987; 59:241-244.
31. Hsia J, Kleiman N, Aguirre F, Chaitman BR, Robert SR, Ross AM. Heparin induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency. J Am Coll Cardiol 1992;20:31-35.
32. O'Connor CM, Meese R, Navetta F, et al. A randomized trial of heparin in conjunction with anistreplase (APSAC) in acute myocardial infarction. Circulation 1991;84(Suppl II): II-571.